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Abstract 
Background. Radiofrequency and cryoballoon pulmonary vein isolation are common approaches 
for paroxysmal atrial fibrillation (AF) treatment, showing similar results in recent multicenter 
studies, including heterogeneous tools and protocols. The aim of this study is to compare 
prospectively in a single, high volume Centre the outcome of paroxysmal AF ablation performed 
specifically by second generation cryoballoon or contact force radiofrequency ablation.  
Methods. Consecutive patients scheduled for paroxysmal AF transcatheter ablation have been 
included and prospectively followed up. Aiming to reduce potential bias deriving from baseline 
characteristics, a propensity score matching analysis has been performed to analyze safety and 
efficacy outcomes. 
Results. Out of consecutive patients undergoing AF transcatheter ablation between January 2015 
and December 2016, 46 patients approached by cryoablation were matched 1:1 by propensity score 
to a similar population treated by last generation radiofrequency ablation. Freedom from AF after 
12 months (76% vs 78%, p=0.804) and incidence of complications (4% vs. 6%, p=0.168) did not 
differ between the two groups. Radiological exposure was higher for the cryoballoon group (11 vs. 
4 min, p<0.001), while procedural duration did not differ (p=0.174). Aiming to assess the potential 
impact of a learning curve in patients undergoing cryoablation, the first third of patients (n=15) 
were compared to the remaining, reporting longer radiological exposure (p<0.001), but similar 
safety and efficacy. 
Conclusion. In this propensity score analysis, last generation cryoballoon and radiofrequency 
catheters for AF ablation present similar efficacy and safety. Cryoablation requires longer 
fluoroscopy exposure compared to radiofrequency, although this is reduced by increased 
experience. 
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Introduction 
Atrial fibrillation (AF) transcatheter ablation is a therapeutic option for rhythm control strategy in 
patients symptomatic from AF, which is receiving continuously wider recommendations due to its 
safety and efficacy on the long term compared to antiarrhythmic drug treatment. In particular, AF 
transcatheter ablation can be proposed for paroxysmal AF when antiarrhythmic drugs fail or are not 
tolerated, or even as an alternative to antiarrhythmic drug treatment when patients wish not to 
undergo chronic pharmacological treatment (1). 
Conversely to persistent AF, in which the optimal transcatheter ablation approach is still under 
investigation, as common practice protocols still reach suboptimal results (2-4), the mainstay for 
paroxysmal AF ablation is pulmonary veins (PV) isolation (5). PV isolation can be effectively 
achieved through different devices (punctual, circular or balloon catheters) and energy sources 
(radiofrequency, cryoenergy, laser). Recently, a large multicentre randomized trial enrolling 
patients with paroxysmal AF compared the two most commonly used energy sources, reporting no 
difference in terms of 1-year outcome alternatively through radiofrequency or cryoballoon ablation 
(6). However, in the latter trial the tools employed and compared were not uniform, as a significant 
amount of patients were not treated by the last generation irrigated radiofrequency catheters, with 
contact force sensing, (a feature that helps to confirm stable contact with the tissue during 
radiofrequency application, resulting in reduced procedural and fluoroscopy times and potentially 
improved safety (7-8)), while few patients were treated with the first-generation cryoballoon. 
The aim of our study is to compare prospectively in a single, high volume Centre the safety and 
efficacy of PV isolation for the treatment of paroxysmal AF by second generation cryoballoon or 
last generation, contact force, radiofrequency catheters. 
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Methods 
Consecutive patients suffering from paroxysmal AF, as classified by the most recent ESC 
guidelines (1), referred to the two Electrophysiology Labs (“Città della Salute e della Scienza” 
Hospital, Turin, Italy, and “Cardinal Massaia” Hospital, Asti, Italy) of our Cardiology Department, 
between January 2015 and December 2016, for a first procedure of transcatheter ablation have 
been included in this prospective study. All patients signed written informed consent to undergo 
the procedure. Clinical characteristics of the population, procedural details and follow-up data 
have been routinely collected and prospectively included in a data registry.  
 
Ablation procedure  
Patients were routinely admitted to the hospital one day before the ablation. The ablation method, 
radiofrequency or cryoballoon, was decided casually. According to the principle of planning one 
cryoablation procedure per week,  among patients with paroxysmal AF and no previous catheter 
ablation attempts, patients referred to cryoablation were selected randomly by the administratives of 
the hospital; the remaining were referred for radiofrequency ablation. Exclusion criteria were: 
previous ablations, contraindications to anticoagulation, cardiac thrombi.  
Oral anticoagulants were continued during the procedure: Warfarin, to maintain an international 
normalized ratio (INR) between 2 and 3 at the time of the procedure; direct oral anticoagulants were 
withheld only the morning of ablation and restarted in the evening. Before ablation, a 
transesophageal echocardiogram was performed in all patients to rule out cardiac thrombi. Magnetic 
resonance or computerized tomography scan was performed routinely to assess left atrial (LA) 
dimension, morphology and PVs pattern.  
After femoral vascular access, a decapolar electrode catheter was positioned in the coronary sinus. 
The LA was accessed by transseptal puncture or through a patent foramen ovale, when present. 
After transseptal puncture, intravenous unfractionated heparin was administered to maintain an 
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activated clotting time (ACT) of above 350 seconds.  
For radiofrequency ablation, a multipolar catheter (Lasso, Biosense Webster, CA, USA) and an 
irrigated-tip ablation catheter with contact force-sensing (Thermocool SmartTouch or Thermocool 
SmartTouch SF, Biosense Webster, CA, USA) were advanced into the LA through the same 
transseptal access. A 3-dimensional reconstruction of the LA and PVs ostia, with the use of an 
electroanatomic mapping system (Carto 3, Biosense Webster, CA, USA) was performed in all 
patients and merged to pre-procedural imaging (cardiac CT or MR). The mainstay of the ablation 
procedure was to obtain complete antral PVs isolation. Contact force was continuously assessed 
during ablation, and optimal contact was defined as a contact force range between 5-15 g, with 
stability set as at least 30% of a 6 seconds time interval over a 3 mm spot. Effective isolation was 
defined by complete elimination of PVs potentials, documented by the circular multipolar catheter. 
For patients treated by cryoablation, after accessing the LA with a single transseptal puncture, the 
cryoballoon (Arctic Front Advance, Medtronic, Minneapolis, USA) including the circular mapping 
catheter (Achieve, Medtronic, Minneapolis, USA) was advanced in the LA. A 3-dimensional 
reconstruction of the LA and PVs ostia, with the use of an electroanatomic mapping system (EnSite 
Precision, St. Jude Medical, Minneapolis, USA) was performed in all patients through the decapolar 
mapping catheter (Livewire, St Jude Medical, Minneapolis, USA), aiming to identify the PVs ostia, 
and merged to pre-procedural imaging to reduce radiation exposure. After PVs cannulation with the 
Achieve catheter, the cryoballoon was placed at each PV ostia, and after confirmation of optimal 
occlusion through contrast dye injection, cryoenergy was delivered. The protocol included a single, 
3-minute lesion in case of optimal parameters (minimal temperature lower than -40°C in 60 seconds 
and/or and time to isolation shorter than 45 seconds), followed by a bonus freeze of 4 minutes in 
case of suboptimal parameters, until complete PV isolation is obtained. Right-sided PVs 
cryoablation was performed during subclavear vein pacing through the decapolar mapping catheter 
and continuous phrenic nerve capturing to prevent phrenic nerve palsy. Pacing was performed just 
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above capture threshold (9), and cryoenergy delivery was interrupted in case of phrenic nerve 
capture loss, waiting for recovery before continuation of the procedure. Effective isolation was 
defined by complete elimination of PVs potentials, determined by the circular multipolar catheter.  
In case of ineffective isolation of any PV following multiple attempts, touch-up with an alternative 
punctual radiofrequency ablation catheter ) was considered to achieve PV isolation. If concomitant 
typical atrial flutter was documented, radiofrequency cavo-tricuspid isthmus ablation was 
performed. 
Following the procedure patients were discharged on oral anticoagulation for at least one month, 
including an antiarrhythmic drug if considered appropriate and tolerated.  
 
Outcomes and follow up 
The main outcomes of the study are: acute success in PV isolation, defined as PV isolation 20 
minutes after the end of ablation with the pre-defined catheter; safety, measured as the incidence 
of major complications, defined as life-threatening complications or those requiring interventions 
or prolonging hospital stay; fluoroscopy time and procedural durations; one-year freedom from 
arrhythmic recurrences. 
Recurrences were detected by routine ambulatory visits (performed at 3, and 12 months and then 
yearly), with collection of patients’ characteristics, symptoms, ECG and 24/48 hours Holter ECG 
recordings. Arrhythmic recurrences were defined as the presence of documented sustained AF, 
atypical atrial flutter or atrial tachycardia lasting more than 30 seconds, respecting a blanking 
period of 3 months following ablation (defined as “early recurrences”).  
Information concerning pharmacological treatment during follow-up, pattern and duration of 
eventual arrhythmic recurrences were collected in the same registry during follow-up visits. 
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Statistical analysis 
To reduce the effect of selection bias in the assignment of patients to either group propensity score 
matching was run on the following baseline characteristics: age, sex, weight, AF duration, 
hypertension, ischemic heart disease, hypertrophic cardiomyopathy, valvular cardiomyopathy, LA 
volume and left ventricular ejection fraction (LVEF). Of note, other potential predictors of outcome 
after AF ablation, as atypical PV pattern, congenital heart disease and obstructive sleep apnea were 
not included as rare or not specifically stratified in the present population. None of other baseline 
variables not included in the propensity score (e.g. pharmacological baseline therapy) did anyway 
report statistically significant values in the two groups. After propensity-score estimation, the two 
groups were matched 1:1 without replacement (nearest-neighbor algorithm), with a caliper equal to 
0.15 of the standard deviation of the logit of the propensity score.  
Out of consecutive patients undergoing a first AF transcatheter ablation between January 2015 and 
December 2016, 46 patients approached by cryoablation were matched 1:1 by propensity score to 
a similar population treated by radiofrequency ablation. In this model, the P-value of the Hosmer–
Lemeshow of goodness of fit was 0.168.  
Continuous variables are reported as mean (standard deviation, SD) or median (range), and 
categorical variables as number (%). Continuous data were compared by one-way ANOVA test, 
after normal distribution was confirmed. Categorical variables were compared in cross-tabulation 
tables by Pearson’s chi-square test or Fisher’s Exact Test. Kaplan Meier curves were used to 
estimate AF recurrence-free survival over time, stratified by the energy source used.  
All tests of significance were two-tailed, and a p value <0.05 was considered statistical significant. 
All analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA). 
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Results 
Baseline characteristics of the two populations after propensity score matching, including overall 
92 patients, are described in Table 1. None of the baseline characteristics was different among the 
two groups. Considering acute efficacy in PV isolation, all patients in the radiofrequency group 
experienced effective isolation, while in the cryoablation group 3 patients (overall 4 PVs) did not; 
in these patients PV isolation was finally achieved by radiofrequency touch-up (Table 2). 
After a mean follow-up of 12 ±5 months, no significant difference in AF recurrences was found 
between the two groups (24% in radiofrequency vs. 22% in cryoablation group, p=0.804) (Figure 
1). Early recurrences presented a non-significant trend towards relationship to long-term relapses 
only among the radiofrequency group (p=0.220). Radiological exposure was higher for patients in 
the cryoablation group (11 min vs. 4 min in the radiofrequency group, p<0.001; 31.08 Gy/cm2 in 
cryoablation vs. 8.42 Gy/cm2 in radiofrequency group, p<0.001), while procedural duration did not 
differ between the two groups (133 min in radiofrequency vs. 124 min in cryoablation group, 
p=0.174). Concerning complications, the overall incidence was comparable between the two 
approaches (4% in radiofrequency vs. 6% in cryoablation group, p=0.168) (Table 2). However, the 
pattern of complications was slightly different: in cryoablation group, 2 patients experienced 
vascular access complications and 1 experienced transient hemoptysis; in radiofrequency group, 1 
patient experienced a vascular access complication and 1 pericardial effusion. No life-threatening 
complications were reported in both groups. 
 
Pulmonary vein anatomy and outcome 
The influence of PV anatomy on the outcome of cryoballoon or radiofrequency PV isolation has 
been analyzed. In particular, 11 (12%) patients presented “atypical” PV anatomy (left common 
trunk and/or right intermediate PV): no difference in the acute outcome of PV isolation nor in the 
incidence of follow-up arrhythmic recurrences (p=0.154) was found among patients with 
“atypical” PV anatomy treated by cryoballoon compared to those treated by radiofrequency (Table 
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3). The only difference was a trend toward lower acute efficacy in achieving isolation of the right 
inferior PV by cryoballoon compared to radiofrequency (96% vs. 100%, p=0.307). Despite similar 
procedural duration (p=0.341), fluoroscopy time was longer for patients treated by cryoballoon 
compared to radiofrequency (p<0.001), also in this subsetting of patients.  
 
Cryoablation learning curve 
Of note, this case sample represents the first experience of our Group with cryoballoon ablation. 
Therefore, aiming to assess the effect of the learning curve on the outcome of cryoballoon ablation, 
the first third of procedures (n=15), were compared to the following ones (Table 4). No difference 
was found in terms of freedom from AF recurrences (p=0.720) and complications (p=0.327). 
However, longer fluoroscopy time was reported within the first cryoablation procedures (15 vs. 9 
min, p<0.001), along with a non-significant trend towards longer procedural duration (133 vs. 119 
min, p=0.120) and more need for intraprocedural touch-up due to failure of cryoballoon PV 
isolation (12% vs. 3%, p=0.230), especially related to isolation of the right inferior PV. 
 
 
 
 
 
 
 
 
 
11 
 
Discussion 
Efficacy and safety outcomes 
The present is a single, high-volume Department prospective study evaluating the outcome of a 
propensity score adjusted population of paroxysmal AF patients alternatively treated by 
radiofrequency or cryoballoon ablation of the latest generation. Second generation cryoballoon and 
radiofrequency contact force catheters proved similar 1-year freedom from AF recurrences after 
ablation. In the present experience ablation efficacy is overall high compared to previous literature; 
interestingly this result was achieved exposing patients to a limited dose of fluoroscopy and without 
affecting safety. 
Previous studies have, in fact, compared radiofrequency and cryoballoon AF ablation,  as the Fire 
and Ice multicenter randomized trial (6), however including a large amount of patients treated by 
previous generation catheters. Another German multicenter registry (10) and a recent meta-analysis 
(11), also assessed this topic; however, by not including specifically last generation catheters, as 
second generation cryoballoon has shown improved outcome compared to the first (12), and 
improved outcome has also been documented in published experiences on contact force catheters 
compared to the previous generations (13-14), these studies potentially encompass bias. On the 
other side a study by Squara et al. (15), including patients treated only with second generation 
cryoballoon and contact force radiofrequency catheters, reported results similar to ours in terms of 
both efficacy and complications; due to the observational design, however, several differences 
among baseline population characteristics were reported, and their impact on the results is 
unknown.  
Of note, isolated early recurrences, frequently described as a transient irritative consequence of 
transcatheter ablation (16), presented a non-significant difference among the two groups. It is 
known that radiofrequency relates to a traumatic effect on the atrial tissue structure, resulting in 
local inflammation and isolated early recurrences during the first months following the procedure. 
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Cryoablation, conversely, presents a more gentle biological effect, potentially limiting irritative 
effects (17). However, in the present experience patients in both groups suffered isolated early 
recurrences, suggesting the presence of a certain amount of myocardial inflammation, probably 
related to the physical contact with the tissue requested to achieve PVs occlusion, also following 
cryoballoon ablation. 
Interestingly, atypical PV patterns were not related to worse acute or mid-term outcome in 
radiofrequency nor in cryoballoon groups. This finding confirms, as previously described by other 
Authors (18-19) also with alternative “one-shot” ablation tools (20), that experienced operators, 
guided by pre-procedural anatomy definition, can manage all PV anatomies indifferently with 
mostly all commonly used ablation tools. The only mark related to PV anatomy is that in 3 patients 
the right inferior PV could not be isolated by cryoballoon. Although not resulting statistically 
significant, and being most probably related to the learning curve in cryoballoon ablation (therefore 
potentially reducible by operators’ experience), this finding warrants consideration. 
Concerning safety, the overall incidence of complications did not differ between the two 
technologies. None of the patients experienced life-threatening complications; more in details, in 
the cryoballoon group there were mainly vascular access-related complications, likely due to the 
larger diameter of the cryoballoon catheter. These results confirm the findings of previous larger 
studies, reporting a similar overall incidence of complications (6,13,14,21). Of note, none of our 
patients experienced phrenic nerve palsy. The explanation may rely on the phrenic nerve monitoring 
method, as we performed just above threshold subclavear vein pacing (9) during right-sided PV 
isolation: this, in our opinion, results in an earlier alert that corresponds to only tangential nerve 
damage, strongly limiting, if not eliminating, the potential risk of persistent phrenic nerve palsy.  
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Fluoroscopy and procedural times 
Radiofrequency ablation procedures were characterized by significantly shorter fluoroscopy times, 
compared to cryoballoon ablation. This finding has already been reported (6), while other studies 
found no significant difference between the two technologies (12-13). The generally lower exposure 
related to radiofrequency ablation can likely be explained by the strong synergy of this approach 
with the electroanatomic mapping systems, enabling, in highly trained Centers, “nearly-zero 
fluoroscopy” ablation procedures (22-23). Conversely, cryoablation usually requires X-ray 
monitoring for manipulation, or at least, as in our study, for confirming PV occlusion by 
venography. Therefore, despite a significant reduction in fluoroscopy time was described with 
second generation catheters and increased operators experience, X-ray exposure probably cannot be 
reduced below a certain level (24). 
Overall procedural duration did not differ between the two technologies. Previous studies reported 
shorter procedural duration for cryoablation, as the balloon-based technology may help to obtain 
isolation faster than point-by-point technologies (6,12-15). The divergence of our study in this 
respect most likely relies on two factors. The first is that a 3-dimensional reconstruction of the LA 
and PVs ostia was performed, to minimize radiation exposure, also in the cryoballoon ablation 
group. This indeed permits to navigate the circular mapping catheter outside the distal cryoballoon 
without continuous fluoroscopy but requires additional mapping time. In our opinion, this 
investment in time is anyway counterbalanced by the clear reduction of radiation exposure that 
reflects in reduced risks for both patients and operators (25-26).  
The second is the inclusion of the first operator’s experience with cryoballoon, although in a 
Department highly trained in radiofrequency, point-by-point AF ablation. The role of the learning 
curve in cryoballoon ablation may therefore have impacted the results of this study producing 
longer procedural time, along with the need in some patients of touch-up radiofrequency 
applications to reach PV isolation. Given this, safety and freedom from AF recurrences among the 
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first cryoablation patients did not differ from the following ones. This finding underlines the 
relatively steep learning curve with cryoballoon ablation (27), most probably impacting on top of 
the need of touch-up to complete PV isolation (in particular regarding the right inferior PV), only 
secondary endpoints, as fluoroscopy time and, procedural duration. In fact, the large extension of 
cryoballoon-induced fibrosis at PV ostia (28) renders PV isolation potentially more reproducible 
and durable (29) with second generation cryoballoon compared to point-by-point radiofrequency 
ablation, resulting in a favorable outcome even in case of limited experience. 
 
Limitations 
First, the limited study size may bound the strength of the results, in particular referring to statistical 
relevance of infrequent features such as procedural complications. Additionally, the non-
randomized design does not exclude the risk of bias in scheduling patients for each of the 
alternative procedures; although propensity score matching limits this issue, the optimal study 
design remains a randomized controlled trial. On the other side, the uniformity related to enrollment 
in a single Department potentially reduces bias introduced by multiple Centers preferences and 
procedural heterogeneities, leading to a standardized work flow in patients’ clinical evaluation, 
selection, procedural details and follow-up evaluations. 
Finally, the extensive use of mapping systems to reduce radiological exposure implies a slight 
prolongation in procedural duration along with a variable (center-dependent) increase in procedural 
costs. However, the low incidence of complications, in particular the absence of thromboembolic 
events or tamponade, underlines the high safety profile of the procedure.  
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Conclusion 
Second generation cryoballoon and last generation radiofrequency contact force ablation are equally 
effective in the mid-term for the treatment of paroxysmal AF, interestingly this result may be 
achieved by exposing patients to employing a very limited dose use of fluoroscopy and with very 
high safety profile. 
Cryoablation may rarely fail to isolate right inferior PV and requires longer fluoroscopy exposure 
compared to radiofrequency ablation,, both this aspects, however, relate to operators’ experience.  
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Tables and Figures 
Table 1. Baseline characteristics of the study population after propensity score matching. 
 Radiofrequency 
(n=46) 
Cryoballoon 
(n=46) 
p-value 
Age, years (SD) 59 (9) 59 (9) 0.946 
Males, n (%) 38 (82) 36 (78) 0.471 
Weight, kg (SD) 79 (12) 78 (11) 0.730 
Height, cm (SD) 175 (9) 174 (8) 0.804 
AF during ablation, n (%) 14 (30) 9 (20) 0.229 
AF duration, months (SD) 51 (57) 57 (51) 0.585 
AF burden, episodes/year 6 (10) 4 (7) 0.213 
Hypertension, n (%) 21 (46) 21 (46) 1.00 
Hyperthyroidism, n (%) 1 (2) 2 (4) 0.557 
Hypothyroidism, n (%) 2 (4) 4 (9) 0.398 
Diabetes, n (%) 3 (7) 3 (7) 1.000 
Heart failure, n (%) 2 (4) 1 (2) 0.557 
Previous TIA/stroke, n (%) 1 (2) 0 (0) 0.315 
Gastropathy, n (%) 8 (18) 13 (28) 0.182 
Sick sinus syndrome, n (%) 4 (8) 5 (11) 0.238 
Hypertrophic cardiomyopathy, n (%) 0 (0) 0 (0) - 
Coronary artery disease, n (%) 3 (7) 3 (7) 1.000 
Valvular cardiomyopathy, n (%) 1 (2) 1 (2) 1.000 
Obstructive sleep apnea, n (%) 0 (0) 0 (0) - 
Antiarrhythmic drugs (baseline), 
Class Ic, n (%) 
Amiodarone, n (%) 
Sotalol, n (%) 
Quinidine, n (%) 
38 (83) 
27 (59) 
7 (15) 
3 (7) 
1 (2) 
43 (93) 
29 (63) 
9 (20) 
6 (13) 
0 (0) 
0.135 
0.669 
0.582 
0.292 
0.315 
Oral anticoagulants (baseline), 
Warfarin, n (%) 
37 (81) 
27 (59) 
38 (83) 
31 (67) 
0.887 
0.388 
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DOAC, n (%) 10 (22) 7 (15) 0.420 
Beta-blockers (baseline), n (%) 24 (52) 26 (57) 0.675 
LA volume, ml (SD) 69 (21) 70 (15) 0.816 
LVEF, % (SD) 61 (6) 61 (5) 0.858 
 
SD: standard deviation; AF: atrial fibrillation; TIA: transient ischaemic attack. DOAC: direct oral 
anticoagulants; LA: left atrium; LVEF: left ventricular ejection fraction.  
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Table 2. Procedural characteristics and follow-up findings of the study population. PV isolation 
refers to acute isolation with the originally employed ablation catheter (without crossover) 
 Radiofrequency 
(n=46) 
Cryoballoon 
(n=46) 
p-value 
LSPV isolation, n (%) 46/46 (100) 46/46 (100) 1.000 
LIPV isolation, n (%) 44/44 (100) 42/43 (98) 0.398 
RSPV isolation, n (%) 46/46 (100) 45/46 (98) 0.315 
RIPV isolation, n (%) 46/46 (100) 44/46 (96) 0.307 
Right isthmus, n (%) 12 (26) 5 (11) 0.011 
Procedural time, min (SD) 133 (35) 124 (30) 0.174 
Fluoroscopy time, min (SD) 4.1 (3) 11 (5) <0.001 
Radiation exposure, Gy/cm2 (SD) 8.42 (5.02) 31.08 (11.41) <0.001 
Complications, n (%) 2 (4) 3 (6) 0.168 
Follow-up, months (SD) 12 (6) 12 (5) 0.655 
Recurrences, n (%) 11 (24) 10 (22) 0.804 
Recurrences with drugs, n (%) 7 (15) 5 (11) 0.536 
Early recurrences, n (%) 5 (10) 2 (4) 0.220 
Antiarrhythmic drugs (follow-up), 
Class Ic, n (%) 
Amiodarone, n (%) 
Sotalol, n (%) 
26 (57) 
17 (37) 
6 (13) 
3 (7) 
36 (78) 
23 (50) 
6 (13) 
8 (17) 
0.116 
0.207 
1.000 
0.108 
Oral anticoagulants (follow-up), 
Warfarin, n (%) 
DOAC, n (%) 
16 (35) 
9 (20) 
7 (15) 
22 (47) 
14 (30) 
8 (17) 
0.204 
0.229 
0.778 
Beta-blockers (baseline), n (%) 28 (61) 23 (50) 0.201 
 
SD: standard deviation; AF: atrial fibrillation; LSPV: left superior pulmonary vein; LIPV: left 
inferior pulmonary vein; RSPV: right superior pulmonary vein; RIPV: right inferior pulmonary 
vein; DOAC: direct oral anticoagulants. 
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Table 3. Procedural details and follow-up of patients presenting “atypical” PV anatomies (left 
common trunk and/or right intermediate accessory PV), stratified according to the type of ablation 
procedure. 
 Overall (n=11) Radiofrequency 
(n=6) 
Cryoballoon (n=5) p-value 
Left common trunk, n 
(%) 
5 (45)  2 (33)  3 (60) - 
Left common trunk 
isolation, n (%) 
11 (100)  (100)  (100) - 
Right intermediate PV, n 
(%) 
7 (64)  5 (83)  2 (40) - 
Right intermediate PV 
isolation, n (%) 
7 (100)  (100)  (100) - 
RSPV isolation, n (%) 11/11 (100) 6/6 (100) 5/5 (100) - 
RIPV isolation, n (%) 11/11 (100) 6/6 (100) 5/5 (100) - 
All PVs isolation, n (%) 11/11 (100) 6/6 (100) 5/5 (100) - 
Procedural time, min 
(SD) 
118 (20) 125 (25) 112 (16) 0.341 
Fluoroscopy time, min 
(SD) 
7 (5) 11.7 (3.5) 2.7 (1.8) <0.001 
Complications, n (%) 0 (0) 0 (0) 0 (0) - 
Recurrences, n (%) 2 (18) 0 (0) 2 (33) 0.154 
Recurrences with drugs, 
n (%) 
1 (9) 0 (0) 1 (17) 0.338 
Early recurrences, n (%) 3 (27) 1 (20) 2 (33) 0.303 
 
PV: pulmonary vein; RSPV: right superior pulmonary vein; RIPV: right inferior pulmonary vein; 
SD: standard deviation. 
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Table 4. Comparison between the acute and mid-term outcome of the first 15 patients treated with 
cryoballoon ablation (learning curve) and the following 30 patients (ordinary procedures). PV 
isolation refers to acute isolation with the originally employed ablation catheter (without crossover) 
 Learning curve (n=15) Ordinary procedures 
(n=31) 
p-value 
Age, years (SD) 61.9 (8) 57.1 (9) 0.087 
Males, n (%) 9 (60) 27 (87) 0.057 
AF duration, months (SD) 46.9 (46) 61.7 (53) 0.366 
Hypertension, n (%) 8 (53) 13 (42) 0.467 
Diabetes, n (%) 2 (13) 1 (3) 0.193 
Heart failure, n (%) 0 (0) 1 (3) 0.482 
Coronary artery disease, n (%) 1 (7) 2 (7) 0.978 
Valvular cardiomyopathy, n (%) 1 (7) 1 (3) 0592 
LA volume, ml (SD) 72 (16) 69 (16) 0.533 
LVEF, % (SD) 62 (3) 61 (6) 0.860 
LSPV isolation, n (%) 16/16 (100) 31/31 (100) - 
LIPV isolation, n (%) 14/15 (93) 28/28 (100) 0.734 
RSPV isolation, n (%) 14/15 (93) 31/31 (100) 0.146 
RIPV isolation, n (%) 13/15 (87) 30/31 (97) 0.193 
RF use, n (%) 2/15 (13) 1/31 (3) 0.168 
Procedural time, min (SD) 132 (29) 120 (30) 0.230 
Fluoroscopy time, min (SD) 15 (5) 8.9 (3) <0.001 
Radiation exposure, Gy/cm2 
(SD) 
44.15 (19.13) 21.74 (9.72) <0.001 
Complications, n (%) 1 (7) 3 (10) 0.327 
Recurrences, n (%) 3 (20) 7 (22) 0.842 
Recurrences with drugs, n (%) 1 (7) 4 (13) 0.524 
 
SD: standard deviation; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LSPV: left 
superior pulmonary vein; LIPV: left inferior pulmonary vein; RSPV: right superior pulmonary 
vein; RIPV: right inferior pulmonary vein; RF: radiofrequency.  
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Figure legends 
Figure 1. Kaplan-Meier estimate of overall freedom from arrhythmic recurrences after 1 year (A), 
and patients AF-free with antiarrhythmic drug treatment (B), according to the technology used for 
catheter ablation. 
 
 
